Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes.
Steinhardt MJ, Wiercinska E, Pham M, Grigoleit GU, Mazzoni A, Da-Via M, Zhou X, Meckel K, Nickel K, Duell J, Krummenast FC, Kraus S, Hopkinson C, Weissbrich B, Müllges W, Stoll G, Kortüm KM, Einsele H, Bonig H, Rasche L. Steinhardt MJ, et al. Among authors: kortum km. J Transl Med. 2020 Apr 21;18(1):177. doi: 10.1186/s12967-020-02337-5. J Transl Med. 2020. PMID: 32316991 Free PMC article.
A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma.
Giesen N, Chatterjee M, Scheid C, Poos AM, Besemer B, Miah K, Benner A, Becker N, Moehler T, Metzler I, Khandanpour C, Seidel-Glaetzer A, Trautmann-Grill K, Kortüm KM, Müller-Tidow C, Mechtersheimer G, Goeppert B, Stenzinger A, Weinhold N, Goldschmidt H, Weisel K, Raab MS. Giesen N, et al. Among authors: kortum km. Blood. 2023 Apr 6;141(14):1685-1690. doi: 10.1182/blood.2022017789. Blood. 2023. PMID: 36608320 Free article. Clinical Trial.
Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma.
Haertle L, Buenache N, Cuesta Hernández HN, Simicek M, Snaurova R, Rapado I, Martinez N, López-Muñoz N, Sánchez-Pina JM, Munawar U, Han S, Ruiz-Heredia Y, Colmenares R, Gallardo M, Sanchez-Beato M, Piris MA, Samur MK, Munshi NC, Ayala R, Kortüm KM, Barrio S, Martínez-López J. Haertle L, et al. Among authors: kortum km. Cancers (Basel). 2023 Jan 15;15(2):532. doi: 10.3390/cancers15020532. Cancers (Basel). 2023. PMID: 36672481 Free PMC article.
Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain.
Lehne M, Kortüm KM, Ramasamy K, Zamagni E, d'Estrubé T, Zhuleku E, Hanna M, Shukla S, Ghiani M, Maywald U, Wilke T, Kellermann L, Perera S. Lehne M, et al. Among authors: kortum km. Eur J Haematol. 2024 May;112(5):701-713. doi: 10.1111/ejh.14161. Epub 2023 Dec 25. Eur J Haematol. 2024. PMID: 38146208
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Nooka AK, Cohen AD, Lee HC, Badros A, Suvannasankha A, Callander N, Abdallah AO, Trudel S, Chari A, Libby EN, Chaudhry M, Hultcrantz M, Kortüm KM, Popat R, Sborov D, Hakim S, Lewis E, Gorsh B, Bhushan B, McKeown A, Gupta I, Opalinska J, Richardson PG, Lonial S. Nooka AK, et al. Among authors: kortum km. Cancer. 2023 Dec 1;129(23):3746-3760. doi: 10.1002/cncr.34987. Epub 2023 Aug 25. Cancer. 2023. PMID: 37622738 Free PMC article.
[Multiple myeloma].
Kortüm KM, Engelhardt M, Rasche L, Knop S, Einsele H. Kortüm KM, et al. Internist (Berl). 2013 Aug;54(8):963-77. doi: 10.1007/s00108-013-3336-2. Internist (Berl). 2013. PMID: 23860514 German.
First targeted therapy in multiple myeloma.
Kortüm KM, Einsele H. Kortüm KM, et al. Blood. 2017 Nov 30;130(22):2359-2360. doi: 10.1182/blood-2017-09-805341. Blood. 2017. PMID: 29191974 Free article. No abstract available.
85 results